Premium
Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia
Author(s) -
Ribera Jordi,
Zamora Lurdes,
Morgades Mireia,
Vives Susana,
Granada Isabel,
Montesinos Pau,
GómezSeguí Inés,
Mercadal Santiago,
Guàrdia Ramon,
Nomdedeu Josep,
Pratcorona Marta,
Tormo Mar,
MartínezLopez Joaquín,
HernándezRivas JesúsMaría,
Ciudad Juana,
Orfao Alberto,
GonzálezCampos José,
Barba Pere,
Escoda Lourdes,
Esteve Jordi,
Genescà Eulàlia,
Solé Francesc,
Feliu Evarist,
Ribera JosepMaria
Publication year - 2019
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.22788
Subject(s) - cdkn2a , minimal residual disease , oncology , medicine , hematopoietic stem cell transplantation , transplantation , lymphoblastic leukemia , disease , progenitor cell , leukemia , stem cell , cancer research , immunology , biology , genetics , cancer
Minimal residual disease (MRD) assessment is an essential tool in contemporary acute lymphoblastic leukemia (ALL) protocols, being used for therapeutic decisions such as hematopoietic stem cell transplantation in high‐risk patients. However, a significant proportion of adult ALL patients with negative MRD still relapse suggesting that other factors (ie, molecular alterations) must be considered in order to identify those patients with high risk of disease progression. We have identified partial IKZF1 gene deletions and CDKN2A/B deletions as markers of disease recurrence and poor survival in a series of uniformly treated adolescent and adult Philadelphia chromosome‐negative B‐cell progenitor ALL patients treated according to the Programa Español de Tratamientos en Hematología protocols. Importantly, CDKN2A/B deletions showed independent significance of MRD at the end of induction, which points out the need for treatment intensification in these patients despite being MRD‐negative after induction therapy.